Merck (MRK) and Jiangsu Hengrui Pharmaceuticals, a global pharmaceutical company focused on scientific and technological innovation, have ...

Li, president, Merck Research Laboratories. “HRS-5346, an investigational oral small molecule inhibitor of Lp(a) formation, is an important addition that expands and complements our cardio ...

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals ...

Merck&Co., Inc., an American multinational biopharmaceutical company, has entered into an agreement to acquire the rights to the experimental drug HRS-5346, developed by China's Jiangsu Hengrui ...

(RTTNews) - Merck & Co., Inc. (MRK), a healthcare company, on Tuesday announced signing of an exclusive license agreement for HRS-5346 with Jiangsu Hengrui Pharmaceuticals Co., Ltd. HRS-5346 is an ...

Merck gains global rights to HRS-5346, an oral Lp(a) inhibitor, excluding Greater China, under a deal with Hengrui Pharma. Hengrui Pharma gets $200M upfront, up to $1.77B in milestones ...

Merck & Co. has agreed to license an investigational oral small molecule lipoprotein (a) inhibitor from Jiangsu Hengrui Pharmaceuticals in a deal potentially worth more than $2 billion to the Chinese ...

MSD has entered an exclusive licence agreement with Hengrui Pharma for the oral small molecule Lp(a) inhibitor, HRS-5346.

The exclusive partnership centers on HRS-5346, an oral inhibitor of lipoprotein(a), or Lp(a), a key risk factor for causing cardiovascular diseases. Per the deal terms, Merck (NYSE:MRK ...

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular disease, excluding Greater China. Merck has entered an exclusive licensing ...

The deal gives Merck global rights (excluding Greater China) to develop and commercialize HRS-5346, an experimental oral treatment targeting lipoprotein(a)a lesser-known but dangerous ...